Breaking News

Novozymes Re-brands Human Albumin Portfolio

January 23, 2013

Combines rAlbumin line under Recombumin name

Novozymes Biopharma has introduced a new brand for its recombinant human albumin (rAlbumin) portfolio, bringing both of its rAlbumin products under its established Recombumin brand. Albucult will be renamed Recombumin Alpha, and Recombumin will now be known as Recombumin Prime. The products, as well as the product codes, will remain the same, but there will be changes reflected on both marketing materials and product labeling.
 
“Novozymes is delighted to announce that it is synchronizing the branding of its rAlbumin products under the Recombumin family name to enhance the clarity of the company’s product offering, while still providing customers with the same superior solutions,” said Dermot Pearson, marketing director, Novozymes Biopharma. “Since we launched our rAlbumins the portfolio has gone from strength-to-strength helping Novozymes to become one of the fastest growing companies in the industry.”
blog comments powered by Disqus
  • Packaging Equipment Close-Up

    Packaging Equipment Close-Up

    Kristin Brooks, Contract Pharma||March 9, 2016
    To meet the wide-ranging needs of the marketplace, suppliers and contract packagers are looking to deliver flexible solutions.

  • Single-use Technology Integral to Advancing Biomanufacturing

    Single-use Technology Integral to Advancing Biomanufacturing

    Nigel Walker, Thatu2019s Nice LLC / Nice Insight||March 9, 2016
    Innovative process technologies are a necessity for today’s biopharmaceutical contract manufacturers

  • Parenteral Outsourcing Trends

    Parenteral Outsourcing Trends

    Tim Wright, Editor||March 9, 2016
    Contract Pharma asked a roundtable of business leaders from Symbiosis, Grifols, Althea, LSNE and Baxter to discuss key trends in the parenteral dosage development and manufacturing market